{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:14:21Z","timestamp":1791422061007,"version":"4.3.3"},"reference-count":32,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>To assess a possible role in tumor progression, the occurrence and type of K- and N-RAS mutations were determined in purified tumor cells, including samples from patients with premalignant monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma (MM), and extramedullary plasma cell (PC) tumors (ExPCTs). Immunophenotypic aberrant PCs were flow sorted from 20 MGUS, 58 MM, and 13 ExPCT patients. One RAS mutation was identified in 20 MGUS tumors (5%), in contrast to a much higher prevalence of RAS mutations in all stages of MM (about 31%). Further, oncogene analyses showed that RAS mutations are not evenly distributed among different molecular subclasses of MM, with the prevalence being increased in MM-expressing cyclin D1 (P = .015) and decreased in MM with t(4;14) (P = .055). We conclude that RAS mutations often provide a genetic marker if not a causal event in the evolution of MGUS to MM. Surprisingly, RAS mutations were absent in bone marrow tumor cells from all patients with ExPCT, a result significantly different from intramedullary MM (P = .001). From 3 of 6 patients with paired intramedullary and extramedullary PCs and identical immunoglobulin heavy chain gene (IgH) sequences, RAS mutations were identified only in extramedullary PCs, suggesting a role for RAS mutations in the transition from intramedullary to extramedullary tumor. (Blood. 2005;105:317-323)<\/jats:p>","DOI":"10.1182\/blood-2004-03-0833","type":"journal-article","created":{"date-parts":[[2004,8,31]],"date-time":"2004-08-31T20:16:52Z","timestamp":1093983412000},"page":"317-323","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":144,"title":["Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors"],"prefix":"10.1182","volume":"105","author":[{"given":"Thomas","family":"Rasmussen","sequence":"first","affiliation":[{"name":"From the Department of Hematology L 54P4, Herlev Hospital, University of Copenhagen, Herlev, Denmark; Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda Naval Hospital, Bethesda, MD; and Section of Hematology, University Hospital, Troms\u00f8, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kuehl","sequence":"additional","affiliation":[{"name":"From the Department of Hematology L 54P4, Herlev Hospital, University of Copenhagen, Herlev, Denmark; Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda Naval Hospital, Bethesda, MD; and Section of Hematology, University Hospital, Troms\u00f8, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Lodahl","sequence":"additional","affiliation":[{"name":"From the Department of Hematology L 54P4, Herlev Hospital, University of Copenhagen, Herlev, Denmark; Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda Naval Hospital, Bethesda, MD; and Section of Hematology, University Hospital, Troms\u00f8, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans E.","family":"Johnsen","sequence":"additional","affiliation":[{"name":"From the Department of Hematology L 54P4, Herlev Hospital, University of Copenhagen, Herlev, Denmark; Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda Naval Hospital, Bethesda, MD; and Section of Hematology, University Hospital, Troms\u00f8, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger Marie S.","family":"Dahl","sequence":"additional","affiliation":[{"name":"From the Department of Hematology L 54P4, Herlev Hospital, University of Copenhagen, Herlev, Denmark; Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda Naval Hospital, Bethesda, MD; and Section of Hematology, University Hospital, Troms\u00f8, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021220511391600_REF1","doi-asserted-by":"crossref","unstructured":"Hallek M, Leif BP, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood.1998;91: 3-21.","DOI":"10.1182\/blood.V91.1.3"},{"key":"2020021220511391600_REF2","doi-asserted-by":"crossref","unstructured":"Liu P, Leong T, Quam L, et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood.1996;88: 2699-2706.","DOI":"10.1182\/blood.V88.7.2699.bloodjournal8872699"},{"key":"2020021220511391600_REF3","doi-asserted-by":"crossref","unstructured":"Neri A, Murphy JP, Cro L, et al. Ras oncogene mutation in multiple myeloma. J Exp Med.1989;170: 1715-1725.","DOI":"10.1084\/jem.170.5.1715"},{"key":"2020021220511391600_REF4","doi-asserted-by":"crossref","unstructured":"Corradini P, Ladetto M, Voena C, et al. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood.1993;81: 2708-2713.","DOI":"10.1182\/blood.V81.10.2708.2708"},{"key":"2020021220511391600_REF5","doi-asserted-by":"crossref","unstructured":"Bezieau S, Devilder MC, Avet-Loiseau H, et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat.2001;18: 212-224.","DOI":"10.1002\/humu.1177"},{"key":"2020021220511391600_REF6","unstructured":"Portier M, Moles JP, Mazars GR, et al. p53 and RAS gene mutations in multiple myeloma. Oncogene.1992;7: 2539-2543."},{"key":"2020021220511391600_REF7","doi-asserted-by":"crossref","unstructured":"Kalakonda N, Rothwell DG, Scarffe JH, Norton JD. Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation. Blood.2001;98: 1555-1560.","DOI":"10.1182\/blood.V98.5.1555"},{"key":"2020021220511391600_REF8","doi-asserted-by":"crossref","unstructured":"Rasmussen T, Jensen L, Honore L, Andersen H, Johnsen HE. Circulating clonal cells in multiple myeloma do not express CD34 mRNA, as measured by single-cell and real-time RT-PCR assays. Br J Haematol.1999;107: 818-824.","DOI":"10.1046\/j.1365-2141.1999.01770.x"},{"key":"2020021220511391600_REF9","doi-asserted-by":"crossref","unstructured":"Dahl IM, Rasmussen T, Kauric G, Husebekk A. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol.2002;116: 273-277.","DOI":"10.1046\/j.1365-2141.2002.03258.x"},{"key":"2020021220511391600_REF10","doi-asserted-by":"crossref","unstructured":"Neri A, Knowles DM, Greco A, McCormick F, Dalla-Favera R. Analysis of RAS oncogene mutations in human lymphoid malignancies. Proc Natl Acad Sci U S A.1988;85: 9268-9272.","DOI":"10.1073\/pnas.85.23.9268"},{"key":"2020021220511391600_REF11","doi-asserted-by":"crossref","unstructured":"McKinzie PB, Parsons BL. Detection of rare K-ras codon 12 mutations using allele-specific competitive blocker PCR. Mutat Res.2002;517: 209-220.","DOI":"10.1016\/S1383-5718(02)00077-3"},{"key":"2020021220511391600_REF12","doi-asserted-by":"crossref","unstructured":"Rasmussen T, Theilgaard-Monch K, Hudlebusch HR, et al. Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities. Br J Haematol.2003;123: 253-262.","DOI":"10.1046\/j.1365-2141.2003.04577.x"},{"key":"2020021220511391600_REF13","unstructured":"Malgeri U, Baldini L, Perfetti V, et al. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. Cancer Res.2000;60: 4058-4061."},{"key":"2020021220511391600_REF14","doi-asserted-by":"crossref","unstructured":"Bar-Eli M, Ahuja HG, Gonsalez-Cadavid N, Foti A, Cline MJ. Analysis of N-RAS exon-1 mutations in myelodysplastic syndromes by polymerase chain reaction and direct sequencing. Blood.1989;73: 281-283.","DOI":"10.1182\/blood.V73.1.281.281"},{"key":"2020021220511391600_REF15","unstructured":"Pellat-Deceunynck C, Barille S, Puthier D, et al. Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. Cancer Res.1995;55: 3647-3653."},{"key":"2020021220511391600_REF16","doi-asserted-by":"crossref","unstructured":"Pellat-Deceunynck C, Barille S, Jego G, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia.1998;12: 1977-1982.","DOI":"10.1038\/sj.leu.2401211"},{"key":"2020021220511391600_REF17","doi-asserted-by":"crossref","unstructured":"Rawstron A, Barrans S, Blythe D, et al. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression. Br J Haematol.1999;104: 138-143.","DOI":"10.1046\/j.1365-2141.1999.01134.x"},{"key":"2020021220511391600_REF18","doi-asserted-by":"crossref","unstructured":"Specht K, Haralambieva E, Bink K, et al. Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Blood.2004; 1120-1126.","DOI":"10.1182\/blood-2003-11-3837"},{"key":"2020021220511391600_REF19","doi-asserted-by":"crossref","unstructured":"Soverini S, Cavo M, Terragna C, et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood.2003; 1588-1594.","DOI":"10.1182\/blood-2002-12-3789"},{"key":"2020021220511391600_REF20","doi-asserted-by":"crossref","unstructured":"Seremetis S, Inghirami G, Ferrero D, et al. Transformation and plasmacytoid differentiation of EBV-infected human B lyphoblasts by ras oncogenes. Science.1989;243: 660-663.","DOI":"10.1126\/science.2536954"},{"key":"2020021220511391600_REF21","unstructured":"Billadeau D, Liu P, Jelinek D, et al. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6. Cancer Res.1997;57: 2268-2275."},{"key":"2020021220511391600_REF22","unstructured":"Billadeau D, Jelinek DF, Shah N, LeBien TW, Van NB. Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6. Cancer Res.1995;55: 3640-3646."},{"key":"2020021220511391600_REF23","doi-asserted-by":"crossref","unstructured":"Rowley M, Van Ness B. Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response. Oncogene.2002;21: 8769-8775.","DOI":"10.1038\/sj.onc.1205387"},{"key":"2020021220511391600_REF24","doi-asserted-by":"crossref","unstructured":"Chatterjee M, Honemann D, Lentzsch S, et al. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6\/gp130\/STAT3 pathway. Blood.2002;100: 3311-3318.","DOI":"10.1182\/blood-2002-01-0102"},{"key":"2020021220511391600_REF25","doi-asserted-by":"crossref","unstructured":"Chesi M, Brents LA, Ely SA, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood.2001;97: 729-736.","DOI":"10.1182\/blood.V97.3.729"},{"key":"2020021220511391600_REF26","doi-asserted-by":"crossref","unstructured":"Chesi M, Bergsagel PL, Kuehl WM. The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression. Curr Opin Hematol.2002;9: 288-293.","DOI":"10.1097\/00062752-200207000-00005"},{"key":"2020021220511391600_REF27","doi-asserted-by":"crossref","unstructured":"Bezieau S, Avet-Loiseau H, Moisan JP, Bataille R. Activating Ras mutations in patients with plasma-cell disorders: a reappraisal. Blood.2002;100: 1101-1102.","DOI":"10.1182\/blood-2002-03-0795"},{"key":"2020021220511391600_REF28","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H, Facon T, Grosbois B, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood.2002;99: 2185-2191.","DOI":"10.1182\/blood.V99.6.2185"},{"key":"2020021220511391600_REF29","doi-asserted-by":"crossref","unstructured":"Keats JJ, Reiman T, Maxwell CA, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood.2003;101: 1520-1529.","DOI":"10.1182\/blood-2002-06-1675"},{"key":"2020021220511391600_REF30","doi-asserted-by":"crossref","unstructured":"Sahara N, Takeshita A, Shigeno K, et al. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol.2002;117: 882-885.","DOI":"10.1046\/j.1365-2141.2002.03513.x"},{"key":"2020021220511391600_REF31","unstructured":"Ocqueteau M, Orfao A, Almeida J, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients: implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol.1998;152: 1655-1665."},{"key":"2020021220511391600_REF32","unstructured":"Corradini P, Inghirami G, Astolfi M, et al. Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia.1994;8: 758-767."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/1\/317\/1705000\/zh800105000317.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/1\/317\/1705000\/zh800105000317.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T20:59:17Z","timestamp":1581541157000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/105\/1\/317\/20009\/Possible-roles-for-activating-RAS-mutations-in-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-03-0833","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,1]]}}}